<DOC>
	<DOCNO>NCT03092284</DOCNO>
	<brief_summary>The present aim perform clinical double-blind placebo-controlled Cardiology Stem Cell Centre - Adipose Stem Cells ( CSCC_ASC ) study heart failure patient investigate regenerative capacity CSCC_ASC treatment .</brief_summary>
	<brief_title>Allogeneic Stem Cell Therapy Heart Failure</brief_title>
	<detailed_description>The primary objective investigate regenerative capacity direct intra-myocardial injection 100 mio . allogeneic CSCC_ASCs patient reduce left ventricular Ejection Fraction ( EF ) ( ≤45 % ) heart failure double-blind placebo-controlled design . A total 81 patient enrol study treat 2:1 randomization either CSCC_ASC placebo ( saline ) . The primary endpoint change leave ventricle end-systolic volume ( LVESV ) 6 month follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . 30 80 year age 2 . Signed informed consent 3 . Chronic stable ischemic heart disease 4 . Symptomatic heart failure New York Heart Association ( NYHA ) class IIIII 5 . EF ≤45 % 6 . Plasma NTproBNP &gt; 300 pg/ml ( &gt; 35 pmol/L ) sinus rhythm plasma NTproBNP &gt; 422 pg/ml ( &gt; 450 pmol/L ) patient atrial fibrillation 7 . Maximal tolerable heart failure medication 8 . Medication unchanged two month prior inclusion 9 . No option percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) 10 . Patients PCI CABG within six month inclusion must new angiography le one month inclusion least four month intervention rule early restenosis 11 . Patients include three month implantation cardiac resynchronisation therapy device 1 . Heart Failure ( NYHA I IV ) 2 . Acute coronary syndrome elevation creatine kinase ( CK ) isoenzyme MB ( CKMB ) troponins , stroke transitory cerebral ischemia within six week inclusion 3 . Other revascularisation treatment within four month treatment 4 . If clinically indicate patient coronary angiography inclusion 5 . Moderate severe aortic stenosis ( valve area &lt; 1.3 mm2 ) valvular disease option surgery . 6 . Diminished functional capacity reason : obstructive pulmonary disease ( COPD ) force expiratory volume ( FEV ) &lt; 1 L/min , moderate severe claudication morbid obesity 7 . Clinical significant anaemia ( haemoglobin &lt; 6 mmol/L ) , leukopenia ( leucocytes &lt; 2 109/L ) , leucocytosis ( leucocytes &gt; 14 109/L ) thrombocytopenia ( thrombocytes &lt; 50 109/L ) 8 . Anticoagulation treatment pause cell injection 9 . Patients reduce immune response 10 . History malignant disease within five year inclusion suspect malignity except treated skin cancer melanoma 11 . Pregnant woman 12 . Other experimental treatment within four week baseline test 13 . Participation another intervention trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>